<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113693</url>
  </required_header>
  <id_info>
    <org_study_id>A98_05BE2118</org_study_id>
    <nct_id>NCT05113693</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 in Healthy Volunteers Under Fed Conditions</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 in Healthy Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective&#xD;
&#xD;
      - Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral&#xD;
      administration in healthy adults under fed condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 3, 2021</start_date>
  <completion_date type="Anticipated">December 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-501, D759, H053</measure>
    <time_frame>Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour</time_frame>
    <description>AUCt: Area under the concentration-time curve from time zero to time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-501, D759, H053</measure>
    <time_frame>Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour</time_frame>
    <description>Cmax: Maximum plasma concentration of the drug</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition.&#xD;
Period 2 - A single dose of 2 tablets(CKD-393 2T) under fed condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 - A single dose of 2 tablets(CKD-393 2T) under fed condition.&#xD;
Period 2 - A single dose of 4 tablets(CKD-501 1T, D759 1T, H053 2T) under fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-393</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501, D759, H053</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult volunteers aged 19 ≤ ~ &lt; 55-year-old.&#xD;
&#xD;
          2. Weight ≥55kg (man) or 45kg (woman), with calculated body mass index (BMI) of 17.5 ≤ ~&#xD;
             &lt; 30.5 kg/m2.&#xD;
&#xD;
          3. Those who have no congenital diseases or chronic diseases within 3 years and have no&#xD;
             abnormal symptoms or findings.&#xD;
&#xD;
          4. Those who are eligible for clinical trials based on laboratory (hematology, blood&#xD;
             chemistry, serology, urology) and 12-lead ECG results at screening.&#xD;
&#xD;
          5. Those who voluntarily decide to participate and agree to comply with the cautions&#xD;
             after fully understand the detailed description of this clinical trial.&#xD;
&#xD;
          6. Those who agree to contraception until the 1 month after last administration of&#xD;
             clinical trial drugs.&#xD;
&#xD;
          7. Those who have the ability and willingness to participate during the entire clinical&#xD;
             trail.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have clinically significant disease or medical history of heart failure,&#xD;
             Hepatopathy, Type 1 Diabetes, Diabetic ketoacidosis, Edema, Renal dysfunction,&#xD;
             galactose intolerance, glucose-galactose malabsorption. And Those who receive&#xD;
             intravenous administration of radioactive iodine contrast agents (for intravenous&#xD;
             urography, venous cholangiography, angiography, computed tomography using contrast&#xD;
             agents, etc.) during clinical trial.&#xD;
&#xD;
          2. Those who have past medical history of gastrointestinal disorder (Crohn's disease,&#xD;
             ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect&#xD;
             the absorption of investigational drug.&#xD;
&#xD;
          3. Those who have the test results written below&#xD;
&#xD;
               -  AST, ALT &gt; 2 times higher than upper normal level&#xD;
&#xD;
          4. Those who exceeding an alcohol consumption criteria(210g/week) within 6 months before&#xD;
             the first administration of investigational drug.&#xD;
&#xD;
               -  Beer 1 glass(250ml, Alcohol contents 5%) = 10g&#xD;
&#xD;
               -  Soju 1 glass(50ml, Alcohol contents 20%) = 8g&#xD;
&#xD;
               -  Wine 1 glass(125ml, Alcohol contents 12%) = 12g&#xD;
&#xD;
          5. Those who exceeding smoking criteia(20 cigarettes/day) within 6 months before the&#xD;
             first administration of investigational drug.&#xD;
&#xD;
          6. Those who received investigational durg by participating in other clinical trial&#xD;
             within 6 months before the first administration of investigational drug.&#xD;
&#xD;
          7. Those who have vital sign written below&#xD;
&#xD;
               -  systolic blood pressure ≥140 mmHg or &lt; 90 mmHg&#xD;
&#xD;
               -  diastolic blood pressure ≥ 90 mmHg or &lt; 60 mmHg&#xD;
&#xD;
          8. Those who have a drug or alcohol abuse history within 1 year before the first&#xD;
             administration of investigational drug.&#xD;
&#xD;
          9. Those who take barbiturate and related (causing induction or inhibition. of&#xD;
             metabolism) drug within 30 days before the first administration of investigational&#xD;
             drug.&#xD;
&#xD;
         10. Those who received Ethical-the-counter (ETC) drugs or Over-the-counter (OTC) drugs&#xD;
             within 10 days before the first administration of investigational drug.&#xD;
&#xD;
         11. Those who donated whole blood within 2 months or apheresis within 1 month before the&#xD;
             first administration of investigational drug.&#xD;
&#xD;
         12. Those who severe acute/chronic medical or mental condition which can increase the&#xD;
             safety risk by administration of investigational drug.&#xD;
&#xD;
         13. Those who have history of hypersensitivity to active pharmaceutical ingredient or&#xD;
             additives.&#xD;
&#xD;
         14. Those who are pregnant or breastfeeding.&#xD;
&#xD;
         15. Those who can't ingest a high fat diet.&#xD;
&#xD;
         16. Those who are deemed inappropriate to participate in clinical trial by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Gul Kim, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Gul Kim, M.D, Ph.D.</last_name>
    <phone>+82-63-259-3480</phone>
    <email>mgkim@jbcp.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

